7th World ADC in Berlin

7th World ADC in Berlin

7th World ADC in Berlin

On 20-22 February 2017, 7th annual World ADC will be convened in Berlin.


Once again Berlin will be the gathering place of distinguished scientists featuring cutting edge research & development in ADC space.


Antibody-Drug Conjugates(ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.


Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.



World ADC Berlin is Europe’s longest running and most detailed antibody-drug conjugate conference.

As the industry’s leading summit for Antibody-Drug Conjugates Development, World ADC Berlin covers every element of ADCs from discovery, development, manufacturing and clinical.


According to ADC Biotechnology, “ADC summit 2016 in Berlin has proved to be a highly useful tool in deciphering the latest trends in the field from all aspects of ADC development and manufacture. This conference is a must for anyone currently working within the ADC arena or looking to move into this exciting field.”



Now in it’s 7th year, World ADC Berlin will enable attendees to develop more clinically effective ADCs. Over 3 days, 56 antibody drug conjugate experts will divulge their cutting-edge research empowering participants to:

Develop next-generation payloads with differentiated mechanisms of action to meet unmet patients needs.


Optimize their linker’s chemistry to improve in vivo stability and minimize off target toxicities


Improve on target efficacy and solid tumor penetration with novel antibody formats


Effectively characterize their ADC compound and submit a comprehensive bioanalytical package as part of their IND filing


Successfully translate into the clinic by managing ADC preclinical efficacy over-estimation


Meet clinical endpoints by maximizing your ADCs clinical therapeutic window with latest advancements in dosing regimen and patient stratification strategies


Optimize their manufacturing processes and QA/QC testing to ensure batch-to-batch reproducibility



It is estimated that more than 300 attendees from 120 organizations take part in this high-profile event.

More than 50% of participants are directors and project team leaders while around 25% of the attendees are scientists and academics.


The registration fee is as follows



For more information, please click here.


Dr. Shima Naghavi, Director of International Affairs